What is Advanced Biomed Inc. Common Stock?
, an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.
ADVB · Verdict
Limited reward · moderate risk
ADVB stands out on balance sheet and volatility, but watch the cash flow signal.
Based on 88% data coverage
ADVB · Verdict
Current ratio 2.09
Top decile vs peers
Weak vs peers
Earnings -70.7% CAGR
80% return on equity
Model-based scoring. For information only — not financial advice.
, an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 7.23M, and a P/E ratio of 1.5x.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.